Compare VanEck Semiconductor ETF (SMH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? VanEck Semiconductor ETF trades at $587.85, while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| SMH | VRTX | |
|---|---|---|
52-Week High | $668.91 | $529.65 |
52-Week Low | $286.43 | $376.62 |
Market Cap | — | $134.25B |
Sector | — | Health |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH, the VanEck Semiconductor ETF, trades at $588.7, up 3.39% ($19.29) in the last session, with a bullish technical signal driven by moving averages. The ETF holds major semiconductor stocks but lacks disclosed financial ratios. Recent news highlights institutional buying, such as Ferguson Shapiro's $4.53 million investment (SEC filing, August 10, 2026), and mixed sentiment from analysts, including a downgrade to Hold by Seeking Alpha (August 10, 2026).
Outlook is cautiously optimistic, supported by AI-driven demand and global semiconductor initiatives, like South Korea's $3.52 billion fund (Reuters, August 10, 2026). Risks include tariff impacts from Trump's polysilicon policy and volatility from concentrated holdings. Investors should weigh growth potential against sector-specific headwinds.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
